Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis (PAFIP2)
Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II)
Sponsor: Centro de Investigación Biomédica en Red de Salud Mental
Listed as NCT02305823, this PHASE4 trial focuses on Psychotic Disorders and Schizophrenia and remains completed. Sponsored by Centro de Investigación Biomédica en Red de Salud Mental, it has been updated 7 times since 2005, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centro de Investigación Biomédica en Red de Salud Mental
- Fundación Marques de Valdecilla
- Instituto de Investigación Marqués de Valdecilla
For direct contact, visit the study record on ClinicalTrials.gov .